Welcome to the GILEAD Sponsored Breakfast Symposium
The Evolving Role of Antibody-Drug Conjugates (ADCs) in Metastatic Triple-Negative Breast Cancer (mTNBC).
You’re invited to an engaging and insightful symposium exploring the evolving role of antibody-drug conjugates (ADCs) in the treatment of metastatic triple-negative breast cancer (mTNBC). As evidence continues to emerge, clinicians are faced with new opportunities and challenges in integrating ADCs into treatment pathways, interpreting HER2-low data, and applying real-world evidence to clinical practice.
Join respected experts Dr Nick Zdenkowski (Chair), Dr Louisa Lo and Dr Catherine Shannon as they explore:
- The latest evidence supporting the use of ADCs in metastatic triple-negative breast cancer.
- Clinical insights into HER2-low disease and the implications for patient management.
- Real-world experience from the Australian TRACIE study and what it means for everyday practice.
- An expert-led Q&A session to explore the rapidly evolving ADC landscape and practical approaches to optimising treatment pathways.
Don’t miss this opportunity to hear from leading experts, gain practical insights into the evolving management of metastatic triple-negative breast cancer, and connect with colleagues from across the oncology community. We look forward to seeing you there!
Meet Our Guest Speakers
We are pleased to introduce the following speakers at the GILEAD sponsored Breakfast Symposium.
Nick Zdenkowski
Conference Guest Speaker
Nick Zdenkowski
Conference Guest Speaker
Dr Zdenkowski is a Medical Oncologist and Medical Advisor with Breast Cancer Trials.
He is the Chair of the BCT Scientific Advisory Committee and sits on the international PALLAS trial Steering Committee. He works on a broad range of breast cancer research, including shared decision-making, clinical trials, and patient-reported outcomes, particularly around neoadjuvant systemic therapy.
His PhD project resulted in the development of a decision aid for patients considering neoadjuvant systemic therapy for breast cancer. He has published widely, from patient-reported outcomes, and systematic reviews through to clinical trial outcomes. His clinical practice is at Lake Macquarie Private Hospital and Maitland Private Hospital in the Hunter Region in NSW Australia.
Catherine Shannon
T&EC Day Speaker
Catherine Shannon
T&EC Day Speaker
Dr Catherine Shannon is a Senior Medical Oncologist at Mater Cancer Care Centre, a member of Mater Research's Clinical Research group and a Senior Lecturer at the University of Queensland. She is the principal or co-investigator on a number of phase I, II and III clinical trials in breast, gynaecological and lung cancer. She is currently on the Executive Committee of the Medical Oncology Group of Australia and the medical oncology consultant for the National Breast and Ovarian Cancer Centre.
Dr Shannon completed a fellowship with the Breast Cancer Unit of the Royal Marsden Hospital, where she researched pre-operative endocrine therapy of breast cancer and the use of biological markers as predictors of response to treatment. She obtained extensive experience in phase I and II trials of novel agents for metastatic breast cancer. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon chaired the committee in writing endocrine therapy guidelines for the management of advanced breast cancer.
Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field.
Dr Shannon practices at Mater Cancer Care Centre in South Brisbane.
Louisa Lo
Symposium Guest Speaker
Louisa Lo
Symposium Guest Speaker
Dr Louisa Lo is a Specialist Physician in Medical Oncology at the Perth Breast Cancer Institute, Breast Cancer Research Centre (BCRC)-WA at Hollywood Private Hospital.
Her immediate focus is on familial breast cancer, cancer prevention, breast cancer management, and new drug studies. Louisa works at the Perth Breast Cancer Institute, Breast Cancer Research Centre (BCRC) WA at Hollywood Private Hospital. She also consults at the breast cancer medical oncology clinics at Sir Charles Gairdner Hospital.
As the Education lead of BCRC-WA, she provides updated clinical education through authoring medical pamphlets, newsletters, and presentations to patients, clinicians, and medical trainees.
Dr Lo graduated from the University of Manchester (UK) with Honours in 2009. She completed her breast cancer oncology fellowship training at the Peter MacCallum Breast Cancer Unit in Melbourne and continued working there as a medical oncologist after her training was complete.
Dr Lo was awarded the prestigious National Health and Medical Research Council PhD scholarship and RACP excellence award in 2017. She is currently completing her PhD in breast cancer liquid biopsy and is interested in using this as a tool to personalise breast cancer treatment for patients.
Dr Lo has been a principal investigator for breast cancer clinical trials and has established her own investigator-initiated studies with sites recruiting in Melbourne and Adelaide.
She has a book chapter and high-impact international cancer journal publications such as the British Journal of Cancer, PLOS Medicine, and Cancer Discovery, and is a reviewer for international cancer journals. She is also a clinical examiner for the FRACP medical physician specialist examinations.